# ARK

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ark-6

- Headquarters: Busan, South Korea
- Website: www.aiark.io/
- Total disclosed funding: $15M
- Latest round: Series A (Sep 11, 2026)
- Investors on record: 7

## About

Based in South Korea, ARK Inc. is a digital healthcare technology company specializing in AI-driven solutions for early detection of chronic diseases, enhancing preventive healthcare measures across various healthcare facilities.Founded in 2018 and headquartered in Busan, South Korea, ARK Inc. focuses on developing AI healthcare technologies. The company has successfully pivoted towards integrating advanced health monitoring solutions into living environments, partnering with major firms such as Zymed and POSCO E&C. The CEO, Hyung-hoe Kim, leads the company following its establishment, fostering strategic relationships within the healthcare sector. ARK Inc. has raised KRW 20 billion in its Series A funding round on March 5, 2026, which constitutes its total funding to date, with investors including AJU IB Investment, DSC Investment, and others. In September 2026, ARK Inc. raised KRW 2 billion in series A funding from new investor T Investment. 
ARK Inc. provides AI-driven healthcare solutions that focus on early detection of chronic disease complications through an innovative platform utilizing retinal imaging technology. Their offerings target healthcare providers, including hospitals and clinics, as well as residential communities, enabling integrated health monitoring. The company has formed collaborations with notable partners to establish AI health lounges in urban apartment complexes, primarily serving the South Korean market.The revenue model for ARK Inc. is based on partnerships with healthcare institutions and technology firms, utilizing subscription and licensing agreements for their AI healthcare platform. Their services are structured on a business-to-business (B2B) basis, with transactions involving upfront implementation fees and ongoing usage fees, facilitating integration into existing healthcare systems.
The company will use the funding to scale its AI-driven healthcare diagnostics platform, strengthen its disease prediction technology, and support market expansion in preventive healthcare and early screening services.

## Funding rounds

- Series A, Sep 11, 2026, $1.5M — T Investment
- Series A, Mar 5, 2026, $14M — AJU IB Investment, SL Investment, DSC Investment, Kiwoom Investment, Wooshin Venture Capital, Platinum Technology Investment

## Investors

- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series A
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series A
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- Kiwoom Investment (https://capitalatlas.ai/funds/kiwoom-investment) — Series A
- Wooshin Venture Capital (https://capitalatlas.ai/funds/wooshin-venture-capital) — Series A
- Platinum Technology Investment (https://capitalatlas.ai/funds/platinum-technology-investment) — Series A
- T Investment (https://capitalatlas.ai/funds/t-investment) — Series A